Fatty Liver Alliance’s Post

🔬 Michigan Medicine's Division of Metabolism, Endocrinology and Diabetes (MEND) is uncovering the secrets behind beta cells in collaboration with Caswell Diabetes Institute (CDI). Beta cells are a crucial component within the pancreas, responsible for producing insulin and regulating blood sugar levels. 🩸 By delving into the intricacies of beta cells, the CDI Islet Program experts aim to advance diabetes research and develop groundbreaking therapies. 💡 Read the article to discover how this research is advancing diabetes therapies: https://lnkd.in/gdBbYi7M #DiabetesResearch #BetaCells #MedicalBreakthroughs #MichiganMedicine

🌟 Efficacy and Safety of SGLT2 Inhibitors With and Without GLP-1 Receptor Agonists 🌟 A recent meta-analysis published in The Lancet Diabetes & Endocrinology explores the efficacy and safety of SGLT2 inhibitors, with or without GLP-1 receptor agonists (GLP-1 RAs). The results are promising for patients with diabetes, cardiovascular, and kidney conditions. 🔍 Case Study: Patient Profile: Name: David Age: 60 Diagnosis: Type 2 Diabetes with Cardiovascular Disease Current Treatment: SGLT2 inhibitor + GLP-1 RA Outcome: Reduced risk of major adverse cardiovascular events (MACE) Decreased hospitalizations for heart failure Slowed progression of chronic kidney disease Discussion Questions: What are the main benefits of combining SGLT2 inhibitors with GLP-1 RAs in managing type 2 diabetes? How do SGLT2 inhibitors improve cardiovascular outcomes in patients with diabetes? What considerations should be made when prescribing these medications together? Interactive Q&A: Q1: How do SGLT2 inhibitors reduce the risk of major adverse cardiovascular events (MACE)? A1: SGLT2 inhibitors reduce MACE by improving glycemic control, lowering blood pressure, and promoting natriuresis, which collectively reduce cardiovascular stress. Q2: Are there any specific patient populations that benefit the most from the combination of SGLT2 inhibitors and GLP-1 RAs? A2: Patients with type 2 diabetes who have a high risk of cardiovascular disease or existing cardiovascular conditions benefit significantly from this combination therapy. Poll: Which outcome is most important to you when choosing a diabetes medication? Cardiovascular protection Kidney health Blood sugar control Weight management Call to Action: 🔗 Learn more about the study here and join our live Q&A session with Dr. Priyadarshini Balasubramanian on the benefits of SGLT2 inhibitors and GLP-1 RAs in diabetes management. Don’t miss this opportunity to get your questions answered! #DiabetesManagement #SGLT2Inhibitors #GLP1RAs #CardiovascularHealth #KidneyHealth #TheLancet #MedicalResearch #Endocrinology #PatientCare References: Priyadarshini Balasubramanian, MD. "Efficacy and Safety of SGLT2 Inhibitors With and Without GLP-1 Receptor Agonists." The Lancet Diabetes & Endocrinology. Stay informed and be part of the conversation! 🌐

🆕 I’m excited to share the publication of this comprehensive review titled "Pathophysiology and therapeutic options for cirrhotic portal hypertension" in The Lancet Gastroenterology & Hepatology, by The Lancet Portal hypertension is a pathological condition resulting from increased resistance to blood flow within the portal venous system. In most cases, this resistance arises due to liver cirrhosis, but can also stem from other hepatic disorders. The elevated portal pressure leads to the development of collateral circulation, such as portosystemic shunts, and can cause severe complications like variceal bleeding, ascites, and hepatic encephalopathy. 🌍 Globally, portal hypertension poses a substantial burden on healthcare systems due to its association with chronic liver diseases and their complications, impacting morbidity and mortality rates. 💫 Join us in exploring the complexities of cirrhotic portal hypertension and uncovering novel approaches to treatment and new avenues of research! Kudos to co-first authors from my lab Sergi Guixé-Muntet and Sergio Quesada Vázquez, PhD 🆓 Access the review here: https://lnkd.in/dB3Bji2E #Cirrhosis #PortalHypertension #Gastroenterology #Hepatology

We are very happy to have contributed data to this is a very important publication in The Lancet showing the importance of therapeutically preserving endogenous insulin producing capacity measured as C-peptide in individuals with new-onset type 1 diabetes. The findings show that improvements in metabolic control measured as HbA1c are directly proportional to the degree of C-peptide preservation. 👇 https://lnkd.in/ecrkGviF This is in line with our own published analyses (Journal of Clinical Endocrinology and Metabolism in 2022, Nowak et al) from the DIAGNODE-2 trial showing how C-peptide preservation with the antigen-specific immunotherapy #Diamyd improves time-in-range, reduces glycemic variability and reduces time above range in new-onset T1D individuals carrying the HLA DR3-DQ2 haplotype. Also, a published retrospective metanalysis in individual-level data from four placebo-controlled clinical trials evaluating Diamyd in type 1 diabetes (Diabetes, Obesity and Metabolism in 2022, Nowak et al) shows a clear correlation between therapeutically preserved C-peptide and improvements in HbA1c. #precisionmedicine #cpeptide #immunotherapy #t1d #hba1c #timeinrange #tir #cgm

📃Scientific paper: Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function Abstract: Background The objective of this study is to retrospectively analyze the correlation between the thyroid hormones and nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients with normal thyroid function. Methods: Totally 586 T2DM patients with normal thyroid function participated in this research and were divided into T2DM without NAFLD (240 cases) group and T2DM with NAFLD (346 cases) group. The NAFLD fibrosis score (NFS) > 0.676 was defined as progressive liver fibrosis and used to categorize the patients into T2DM without progressive liver fibrosis group (493 cases) and T2DM with progressive liver fibrosis group (93 cases). Results: The results indicated that the levels of free triiodothyronine (FT3), total triiodomethylamine (TT3) and FT3/free thyroxine ratio (FT3/FT4) were significantly higher while the FT4 level was lower in T2DM with NAFLD group than that in T2DM without NAFLD group ( p < 0.05 ). The levels of FT3, FT4, TT3 and TT4 in patients with progressive liver fibrosis were significantly lower in patients with progressive liver fibrosis than that in patients without progressive liver fibrosis ( p < 0.05 ). Logistic regression analysis showed a positive connection between FT3/FT4 ratio and NAFLD ( p = 0.038 ), a negative relationship between FT4 level and NAFLD ( p = 0.026 ), between the levels of FT4, TT3 and total thyroxine (TT4) and the risk of progressive hepatic fibrosis ( p = 0.022, p = 0.007, p = 0.046 ). Conclusion Ther... Discover the rest of the scientific article on es/iode ➡️https://etcse.fr/jQPUz

📃Scientific paper: Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function Abstract: Background The objective of this study is to retrospectively analyze the correlation between the thyroid hormones and nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients with normal thyroid function. Methods: Totally 586 T2DM patients with normal thyroid function participated in this research and were divided into T2DM without NAFLD (240 cases) group and T2DM with NAFLD (346 cases) group. The NAFLD fibrosis score (NFS) > 0.676 was defined as progressive liver fibrosis and used to categorize the patients into T2DM without progressive liver fibrosis group (493 cases) and T2DM with progressive liver fibrosis group (93 cases). Results: The results indicated that the levels of free triiodothyronine (FT3), total triiodomethylamine (TT3) and FT3/free thyroxine ratio (FT3/FT4) were significantly higher while the FT4 level was lower in T2DM with NAFLD group than that in T2DM without NAFLD group ( p < 0.05 ). The levels of FT3, FT4, TT3 and TT4 in patients with progressive liver fibrosis were significantly lower in patients with progressive liver fibrosis than that in patients without progressive liver fibrosis ( p < 0.05 ). Logistic regression analysis showed a positive connection between FT3/FT4 ratio and NAFLD ( p = 0.038 ), a negative relationship between FT4 level and NAFLD ( p = 0.026 ), between the levels of FT4, TT3 and total thyroxine (TT4) and the risk of progressive hepatic fibrosis ( p = 0.022, p = 0.007, p = 0.046 ). Conclusion Ther... Continued on ES/IODE ➡️ https://etcse.fr/jQPUz ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Abstract The vitamin C deficiency disease scurvy is characterised by musculoskeletal pain and recent epidemiological evidence has indicated an association between suboptimal vitamin C status and spinal pain. Furthermore, accumulating evidence indicates that vitamin C administration can exhibit analgesic properties in some clinical conditions. The prevalence of hypovitaminosis C and vitamin C deficiency is high in various patient groups, such as surgical/trauma, infectious diseases and cancer patients. A number of recent clinical studies have shown that vitamin C administration to patients with chronic regional pain syndrome decreases their symptoms. Acute herpetic and post-herpetic neuralgia is also diminished with high dose vitamin C administration. Furthermore, cancer-related pain is decreased with high dose vitamin C, contributing to enhanced patient quality of life. A number of mechanisms have been proposed for vitamin C's analgesic properties. Herein we propose a novel analgesic mechanism for vitamin C; as a cofactor for the biosynthesis of amidated opioid peptides. It is well established that vitamin C participates in the amidation of peptides, through acting as a cofactor for peptidyl-glycine α-amidating monooxygenase, the only enzyme known to amidate the carboxy terminal residue of neuropeptides and peptide hormones. Support for our proposed mechanism comes from studies which show a decreased requirement for opioid analgesics in surgical and cancer patients administered high dose vitamin C. Overall, vitamin C appears to be a safe and effective adjunctive therapy for acute and chronic pain relief in specific patient groups.

🚨 New Study Alert 🚨 the latest research highlights a significant link between #UlcerativeColitis (#UC) and abnormal #LiverFunctionTests (#LFTs). 🩺 Key Findings: 69.4% of UC patients without known liver disorders had elevated LFTs. Liver injury was present in 21.8% of patients. Thiopurine treatment increased the risk of persistent elevated LFTs, while steroids had a protective effect. 🔍 This underscores the crucial need for regular screening of hepatobiliary disorders in UC patients. Discover more about our findings and their implications! #IBD #Hepatology #Gastroenterology #MedicalResearch #Healthcare Jonel Trebicka https://lnkd.in/eq8eK42m

#hepatology Are you interested in the role of #innovation in #healthcare but you are not in my group with thousands of professionals sharing their #data and #experiences without any other scope? Feel free to join the group here https://lnkd.in/edh2sxF and comment these news by Journal of Hepatology

Excited to share our latest publication in #EndocrinePractice (IF 4.2), the flagship journal of the American Association of Clinical Endocrinology #AACE, titled “Effect of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure in patients with type-2 diabetes and hypertension: an updated meta-analysis.” Link: https://lnkd.in/d64ZnQwU This updated #metaanalysis evaluated the potential benefits of sodium-glucose cotransporter 2 (#SGLT2) inhibitors in regulating blood pressure in patients with #type2diabetes and #hypertension. This meta-analysis of ten #RCTs concluded that SGLT2 inhibitors significantly reduce 24-hour ambulatory systolic blood pressure (WMD = -5.08 mmHg, 95% CI: -7.02 to -3.14, p <0.00001) as well as diastolic blood pressure (WMD = -2.73 mmHg, 95% CI: -4.25 to –1.20, p = 0.0005). Our findings recommend that SGLT2 inhibitors may be considered an effective treatment option for lowering blood pressure in addition to standard care in hypertensive patients with type 2 diabetes mellitus. #medicalresearch #scientificpublication #earlycareerresearchers #healthcareinnovation